Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
|Videos|July 22, 2018
AACP President-Elect Discusses Challenges and Opportunities
In this video, David D. Allen, PhD, RPh, FASHP, the president-elect of the American Association of Colleges of Pharmacy (AACP) and the dean of the University of Mississippi School of Pharmacy, discusses the challenges and opportunities that he expects to encounter as he takes on his new role in the AACP.
Advertisement
In this video, David D. Allen, PhD, RPh, FASHP, the president-elect of the American Association of Colleges of Pharmacy (AACP) and the dean of the University of Mississippi School of Pharmacy, discusses the challenges and opportunities that he expects to encounter as he takes on his new role in the AACP. This interview was filmed at the AACP's Pharmacy Education 2018 meeting in Boston, Massachusetts.
Advertisement
Related to this article
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
2
Beyond Prescription Volume: Measuring the Pharmacist’s Value
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5